Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX

BACKGROUND: Biomarkers predicting treatment response may be used to stratify pancreatic ductal adenocarcinoma (PDAC) patients for therapy. The aim of this study was to identify circulating tumor DNA (ctDNA) mutations that associate with tumor progression during FOLFIRINOX chemotherapy, and overall s...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Sijde, Fleur, Azmani, Zakia, Besselink, Marc G., Bonsing, Bert A., de Groot, Jan Willem B., Groot Koerkamp, Bas, Haberkorn, Brigitte C. M., Homs, Marjolein Y. V., van IJcken, Wilfred F. J., Janssen, Quisette P., Lolkema, Martijn P., Luelmo, Saskia A. C., Mekenkamp, Leonie J. M., Mustafa, Dana A. M., van Schaik, Ron H. N., Wilmink, Johanna W., Vietsch, Eveline E., van Eijck, Casper H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377319/
https://www.ncbi.nlm.nih.gov/pubmed/34422118
http://dx.doi.org/10.1177/17588359211033704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377319/
https://www.ncbi.nlm.nih.gov/pubmed/34422118
http://dx.doi.org/10.1177/17588359211033704

Ejemplares similares